IBDEI21X ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,497,0)
 ;;=ESTABLISHED PATIENT^1^36
 ;;^UTILITY(U,$J,358.4,498,0)
 ;;=CONSULTATIONS^3^36
 ;;^UTILITY(U,$J,358.4,499,0)
 ;;=BIOPSIES^1^37
 ;;^UTILITY(U,$J,358.4,500,0)
 ;;=INJECTIONS^2^37
 ;;^UTILITY(U,$J,358.4,501,0)
 ;;=OTHER^3^37
 ;;^UTILITY(U,$J,358.4,502,0)
 ;;=MALE^8^38
 ;;^UTILITY(U,$J,358.4,503,0)
 ;;=ADRENAL^1^38
 ;;^UTILITY(U,$J,358.4,504,0)
 ;;=BONE/CALCIUM^2^38
 ;;^UTILITY(U,$J,358.4,505,0)
 ;;=DIABETES^4^38
 ;;^UTILITY(U,$J,358.4,506,0)
 ;;=LIPIDS^7^38
 ;;^UTILITY(U,$J,358.4,507,0)
 ;;=PITUITARY^14^38
 ;;^UTILITY(U,$J,358.4,508,0)
 ;;=REPRODUCTIVE ENDOCRINOLOGY^17^38
 ;;^UTILITY(U,$J,358.4,509,0)
 ;;=THYROID^21^38
 ;;^UTILITY(U,$J,358.4,510,0)
 ;;=MISCELLANEOUS^11^38
 ;;^UTILITY(U,$J,358.4,511,0)
 ;;=CELLULITIS^3^38
 ;;^UTILITY(U,$J,358.4,512,0)
 ;;=EYE^5^38
 ;;^UTILITY(U,$J,358.4,513,0)
 ;;=HEPATITIS^6^38
 ;;^UTILITY(U,$J,358.4,514,0)
 ;;=MALNUTRITION^9^38
 ;;^UTILITY(U,$J,358.4,515,0)
 ;;=MENTAL HEALTH^10^38
 ;;^UTILITY(U,$J,358.4,516,0)
 ;;=NEUROLOGICAL MANIFESTATIONS^12^38
 ;;^UTILITY(U,$J,358.4,517,0)
 ;;=PERIPHERAL CIRC DISORDER^13^38
 ;;^UTILITY(U,$J,358.4,518,0)
 ;;=PULMONARY^15^38
 ;;^UTILITY(U,$J,358.4,519,0)
 ;;=RENAL^16^38
 ;;^UTILITY(U,$J,358.4,520,0)
 ;;=SCI/PARALYTIC SYNDROME^18^38
 ;;^UTILITY(U,$J,358.4,521,0)
 ;;=SKIN ULCERS^19^38
 ;;^UTILITY(U,$J,358.4,522,0)
 ;;=STROKE LATE EFFECTS^20^38
 ;;^UTILITY(U,$J,358.4,523,0)
 ;;=HEAD AND NECK-MISCELLANEOUS^1^39
 ;;^UTILITY(U,$J,358.4,524,0)
 ;;=NOSE AND SINUSES^3^39
 ;;^UTILITY(U,$J,358.4,525,0)
 ;;=ORAL CAVITY^4^39
 ;;^UTILITY(U,$J,358.4,526,0)
 ;;=OTOLOGY^5^39
 ;;^UTILITY(U,$J,358.4,527,0)
 ;;=PHARYNX AND LARYNX^6^39
 ;;^UTILITY(U,$J,358.4,528,0)
 ;;=MISCELLANEOUS PROCEDURES^2^39
 ;;^UTILITY(U,$J,358.4,529,0)
 ;;=ESTABLISHED PATIENT^1^40
 ;;^UTILITY(U,$J,358.4,530,0)
 ;;=CONSULTATIONS^3^40
 ;;^UTILITY(U,$J,358.4,531,0)
 ;;=NEW PATIENT^2^40
 ;;^UTILITY(U,$J,358.4,532,0)
 ;;=POST OP^4^40
 ;;^UTILITY(U,$J,358.4,533,0)
 ;;=ALIMENTARY TRACT^1^41
 ;;^UTILITY(U,$J,358.4,534,0)
 ;;=FRACTURES^3^41
 ;;^UTILITY(U,$J,358.4,535,0)
 ;;=NEOPLASMS^8^41
 ;;^UTILITY(U,$J,358.4,536,0)
 ;;=OTOLOGY^10^41
 ;;^UTILITY(U,$J,358.4,537,0)
 ;;=METASTATIC SITES^7^41
 ;;^UTILITY(U,$J,358.4,538,0)
 ;;=RESPIRATORY TRACT ^11^41
 ;;^UTILITY(U,$J,358.4,539,0)
 ;;=HEAD AND NECK^4^41
 ;;^UTILITY(U,$J,358.4,540,0)
 ;;=OTHER^9^41
 ;;^UTILITY(U,$J,358.4,541,0)
 ;;=BLINDNESS^2^41
 ;;^UTILITY(U,$J,358.4,542,0)
 ;;=HEPATITIS^5^41
 ;;^UTILITY(U,$J,358.4,543,0)
 ;;=LATE EFFECT CVA^6^41
 ;;^UTILITY(U,$J,358.4,544,0)
 ;;=NEW PATIENT^3^42
 ;;^UTILITY(U,$J,358.4,545,0)
 ;;=ESTABLISHED PATIENT^2^42
 ;;^UTILITY(U,$J,358.4,546,0)
 ;;=CONSULTATIONS^4^42
 ;;^UTILITY(U,$J,358.4,547,0)
 ;;=EYE CODES^1^42
 ;;^UTILITY(U,$J,358.4,548,0)
 ;;=REFRACTION^7^43
 ;;^UTILITY(U,$J,358.4,549,0)
 ;;=GLASSES/CONTACT LENSES^2^43
 ;;^UTILITY(U,$J,358.4,550,0)
 ;;=SPECIAL OPHTHALMIC SERVICES^9^43
 ;;^UTILITY(U,$J,358.4,551,0)
 ;;=PROCEDURES^6^43
 ;;^UTILITY(U,$J,358.4,552,0)
 ;;=LASER PROCEDURES^4^43
 ;;^UTILITY(U,$J,358.4,553,0)
 ;;=RETINA PROCEDURES^8^43
 ;;^UTILITY(U,$J,358.4,554,0)
 ;;=MEDICATIONS^5^43
 ;;^UTILITY(U,$J,358.4,555,0)
 ;;=INTRAVITREAL INJECTIONS^3^43
 ;;^UTILITY(U,$J,358.4,556,0)
 ;;=EDUCATION/COUNSELING^1^43
 ;;^UTILITY(U,$J,358.4,557,0)
 ;;=ORBIT/EYELID/LACRIMAL^9^44
 ;;^UTILITY(U,$J,358.4,558,0)
 ;;=ANTERIOR SEGMENT/LACRIMAL^2^44
 ;;^UTILITY(U,$J,358.4,559,0)
 ;;=LENS/CATARACT^6^44
 ;;^UTILITY(U,$J,358.4,560,0)
 ;;=RETINA/VITREOUS/CHOROID^10^44
 ;;^UTILITY(U,$J,358.4,561,0)
 ;;=NEUROLOGIC EYE DISEASE^8^44
 ;;^UTILITY(U,$J,358.4,562,0)
 ;;=MEDICAL/SYSTEMIC/TRAUMA/OTHER^7^44
 ;;
 ;;$END ROU IBDEI21X
